Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial
June 03, 2024 08:20 ET
|
Microbot Medical Inc.
BRAINTREE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces that it has...
Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial
June 03, 2024 08:15 ET
|
Autonomix Medical, Inc.
Company plans to release topline results from “lead-in” patients (n=5) imminently THE WOODLANDS, TX, June 03, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the...
Molecular Templates, Inc. Provides Interim Update
June 03, 2024 08:11 ET
|
Molecular Templates, Inc.
Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients.Early pre-clinical and clinical data demonstrate the potential of MT-0169...
Maris-Tech Receives New Order for $225,000 From a Military Drone Manufacturer for a Unique Solution for Unmanned Aircraft Systems
June 03, 2024 08:10 ET
|
Maris-Tech Ltd.
The advanced video payload for drones will be based on Maris-Tech’s Uranus technology Rehovot, Israel, June 03, 2024 (GLOBE NEWSWIRE) -- Maris-Tech Ltd. (Nasdaq: MTEK) ("Maris-Tech" or the...
InnovAge PACE Recertified as a Great Place to Work
June 03, 2024 08:05 ET
|
InnovAge
InnovAge PACE has been recertified as a Great Place to Work. President and CEO Patrick Blair shares results, accolades, and gratitude.
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
June 03, 2024 08:05 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and...
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
June 03, 2024 08:02 ET
|
Rhythm Pharmaceuticals, Inc.
RYTM CEO at David Meeker at Goldman Sachs Global Healthcare Conference June 10.
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
June 03, 2024 08:01 ET
|
Mainz BioMed NV
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
June 03, 2024 08:00 ET
|
Denali Therapeutics Inc.
START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological products for rare diseasesDNL126 was selected as...
BriaCell Presents Clinical Efficacy Data at ASCO 2024
June 03, 2024 08:00 ET
|
BriaCell Therapeutics Corp.
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of...